Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis

Osteoporosis, Post-Menopausal Clinical Trial

Official title:
Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis

Status Completed

Clinical Trial Summary

To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, are able to produce reliable changes in the bone marker in a severe osteoporotic population

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00532545
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 4
Start date	April 2003
Completion date	April 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00532207` - Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis	Phase 3
Completed	`NCT00018447` - Combination Osteogenic Therapy in Established Osteoporosis	Phase 2
Completed	`NCT00532246` - Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo	Phase 4
Completed	`NCT00543023` - A Study of the Treatment of Postmenopausal Women With Osteoporosis	Phase 3
Completed	`NCT00927186` - Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women	Phase 4
Completed	`NCT00543218` - PTH Comparison in Post Menopausal Women	Phase 3
Completed	`NCT00532428` - Long Term Effects of Raloxifene Treatment on Bone Quality	Phase 4